Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of brexpiprazole orally disintegrating tablet vs conventional tablet in healthy adult males
jRCT1080224586Phase 1Completed
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Start
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of brexpiprazole in schizophrenia and major depressive disorder (MDD) (3 arms), sponsored by Otsuka Pharmaceutical Co., Ltd. Primary endpoint: Primary pharmacokinetic endpoints. Started Mar 2019; status: completed.
02
Drugs
brexpiprazole
03
Conditions
schizophreniamajor depressive disorder (MDD)
Beyond the preview
Go deeper on jRCT1080224586.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1080224586.